Results were consistent assessing lowered BMI via GIPR/GLP1R and GIPR in the MVP cohort, though mediation effects were attenuated, underscoring a novel behavioral mechanism through which GLP1R and GIPR agonists may reduce CAD risk. The gene discussed is GIPR; the disease is coronary artery disorder.